Pricing and commercial policies are central to capturing the full value of innovation while ensuring patient access and payer alignment. Life Sciences companies face growing scrutiny from regulators, payers, and healthcare systems, alongside very different pricing realities depending on whether products are reimbursed or subject to free pricing. Misaligned pricing strategies or rigid commercial policies can lead to delayed access, underperformance in key markets, or loss of competitive advantage.
For reimbursed products and solutions, such as pharmaceuticals, biologics, advanced diagnostics, and certain MedTech products, pricing decisions are tightly linked to clinical value, health economics, and payer negotiations. Pricing strategies must account for national reimbursement frameworks, health technology assessment requirements, international reference pricing, and lifecycle considerations, particularly for specialty therapies and rare diseases. Commercial policies must support coherent price corridors, disciplined discounting, and alignment between global strategy and local execution.
For non-reimbursed or freely priced offerings, including parts of MedTech, Consumer Health, digital health solutions, and services, pricing is shaped by market dynamics, competitive intensity, customer willingness to pay, and brand positioning. In these contexts, pricing and commercial policies play a direct role in driving adoption, volume, and profitability, and must be closely integrated with marketing, channel strategy, and promotional effectiveness.
We help Life Sciences companies develop evidence-based pricing strategies and commercial policies adapted to both environments. Our approach combines market analysis, payer and reimbursement insights, value demonstration, and competitor benchmarking to define pricing architectures aligned with stakeholder expectations. We advise on discounting frameworks, contracting strategies, promotional policies, and governance mechanisms to ensure consistency across regions and channels.
For Pharma and Biotech, we design launch and lifecycle pricing strategies, including value-based or outcome-linked models. For MedTech and Diagnostics, we support pricing in hospital procurement environments, bundle pricing, and device–service combinations. For Consumer Health and services, we define pricing and promotion policies that maximize market share, margin, and brand equity. By integrating strategic design with operational execution, we enable clients to capture value, support access, and remain agile in the face of evolving market and regulatory dynamics.
